Harpoon Therapeutics said it raised $45 million of Series B financing in a deal co-led by Arix Bioscience and New Leaf Venture Partners and joined by new investor Taiho Ventures and existing investor MPM Capital.

Arix Investment Manager Mark Chin and New Leaf Managing Director Ron Hunt will join the board.

The new capital will support the development of Harpoon’s T-cell immuno-oncology therapies.